ClinicalTrials.gg
RecruitingNCT06773312Updated Mar 10, 2025

BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.

A Phase 1 interventional study of BC001+Sintilimab+XELOX in Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma, sponsored by Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing sintilimab in Stomach Neoplasms — 29 open to participants now, 35 under way, 2 of them phase 3. sintilimab · Stomach Neoplasms.

Planned enrollment
9th of 44
80 · median 40
Started
2025
with 4 others
Phase 1
Only one
of the 44
Primary completion
2026-10
later than 22 of 34 live
Registered
34th of 44
by date

Among the 44 studies testing sintilimab in Stomach Neoplasms, this one is the 9th largest by planned enrollment, is one of 5 that started in 2025, is the only one in phase 1, reaches primary completion later than 22 of the 34 other live ones, and was the 34th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

29 of the 44 studies testing sintilimab in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

23 more — sign in →

By country, each count listing its studies:

All 29 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing sintilimab in Stomach Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn the efficaty and safety of BC001 in combination with Sintilimab and XELOX in treating patients with advanced or metastatic GC/GEJ.

Participants will:

Be administered with BC001, Sintilimab and Oxaliplatin once every three weeks for up to 24 months or until disease progression as per RECIST 1.1 or withdrawal from this study.

Take Capecitabine once daily in the first two weeks of each three-week treatment cycle for up to 24 months or until disease progression as per RECIST 1.1 or withdrawal from this study.

Read the detailed description

This trial is an open-label Phase I clinical trial, which is divided into the dose escalation phase and the dose expansion phase. It aims to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics and preliminary efficacy of BC001 in combination with Sintilimab and XELOX, and to determine the recommended Phase 2 dose (RP2D) and preliminary efficacy of BC001 in combination with Sintilimab and XELOX in the treatment of patients with HER-2 negative advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJ) who have never received systemic treatment before.

The dose escalation phase adopts a 3+3 dose escalation design and three dose groups are planned initially.

The dose expansion study will recommend two appropriate dose groups based on data from the dose escalation phase, and 30 subjects planned to be enrolled in each group. According to the safety and efficacy of each group, one of the doses will be selected and determined as the recommended Phase 2 dose (RP2D).

03

Conditions studied

  • Advanced or Metastatic Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma

Browse trials for

Keywords

  • gastroesophageal junction adenocarcinoma
  • VEGFR2
  • gastric cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must be able to understand and voluntarily sign the written .
  2. Subjects must be willing and able to complete the study procedures and follow-up examinations.
  3. Male or female subjects aged between 18 and 75 years old (including 18 and 75 years old).
  4. negative patients with advanced or gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJ) (according to the 8th edition of AJCC/UICC TNM staging) confirmed by histopathology or cytopathology, who have never received systemic treatment before (the time interval from the end of previous treatment/adjuvant treatment to the recurrence of the disease > 6 months will be regarded as untreated).
  5. According to version 1.1, there must be at least one measurable tumor lesion shown by CT or MRI examination.
  6. Subjects with normal oral intake.
  7. (Eastern Cooperative Oncology Group) performance score of 0 - 1.
  8. Expected survival period is greater than 3 months.
  9. There is no serious hematological, hepatic or renal function abnormality, meeting the following laboratory test results: the (ANC) should be ≥1.5×10⁹/L, (PLT) ≥100×10⁹/L, and (HGB) ≥90g/L; Serum creatinine (Cr) ≤1.5× the (ULN). When Cr > 1.5×ULN, , and rate (Ccr)≥ 60mL/min(calculated according to the Cockcroft - Gault formula); the qualitative urine protein should be ≤1 +, or if the qualitative urine protein ≥2 +, the 24-hour urine protein \< 1g; total (TBIL) ≤1.5×ULN or ≤3×ULN (for patients with liver cancer or liver metastases), (AST) and aspartate aminotransferase (ALT) ≤3.0×ULN or ≤5×ULN (for patients with liver cancer or liver metastases), alkaline phosphatase (ALP) ≤2.5×ULN or ≤5×ULN (for patients with liver cancer or liver metastases); the (INR) or prothrombin time T (PT) ≤1.5×ULN, and the activated partial thromboplastin time (APTT) ≤1.5×ULN.
  10. Male or female subjects should take effective measures during the treatment period and within 6 months after the last dose administration.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have undergone major organ surgical operations (excluding needle ) or had significant trauma within 4 weeks prior to the first use of the study drug, or who need to undergo elective surgeries during the trial period.
  2. Subjects whose original lesions have invaded the central nervous system (CNS) with symptoms, are unstable or require high-dose (≥10mg dexamethasone or equivalent dose) to achieve control.
  3. Subjects suffering from other primary , except for malignancies with low risk and low death risk (5-year survival rate > 90%), such as malignancies that have been cured and have not within 3 years before enrollment in the study; completely resected basal cell and squamous cell skin cancers; completely resected carcinomas in situ of any type.
  4. Subjects with active infections (such as viral, bacterial or fungal infections) that require systemic treatment.
  5. Subjects currently suffering from interstitial lung disease (except for radiation-induced pulmonary fibrosis that does not require hormone treatment).
  6. Subjects with a history of active bleeding within the past 4 weeks or at risk of gastrointestinal perforation, or with a history of recent surgeries that have not healed or with a history of wound complications caused by surgical operations.
  7. Subjects who had gastrointestinal bleeding within 3 months prior to the use of the study drug and without evidence verified by endoscopy or colonoscopy that they have recovered; subjects with severe gastrointestinal diseases within 2 weeks prior to the use of the study drug.
  8. Subjects with a history of severe cardiovascular and cerebrovascular diseases, including but not limited to: Having severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, grade II - III atrioventricular block, etc.; Having suffered from acute coronary syndrome, congestive heart failure, aortic dissection, stroke/ or other grade 3 or above cardiovascular and cerebrovascular events within 6 months prior to the first dose administration; Having heart failure of (NYHA) class > II or (LVEF) \< 50%; Having a baseline interval corrected for heart rate calculated by the Fridericia formula > 450 msec (for males) and > 470 msec (for females); Having any factors that increase the risk of QTc prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, a family history of long QT syndrome or using any concomitant drugs known to prolong the QT interval.

    Having a diastolic blood pressure ≥ 100 mmHg or a systolic blood pressure ≥ 160 mmHg after standardized treatment.

  9. Subjects who have received treatments such as colony-stimulating factors and erythropoietin within 2 weeks prior to the use of the study drug.
  10. Subjects who have been vaccinated with within 4 weeks prior to the use of the study drug. Live vaccines include but are not limited to the following: measles, mumps, rubella, varicella/zoster (chickenpox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG) and typhoid vaccines. Seasonal influenza vaccines for injection are usually inactivated virus vaccines, so their use is permitted; intranasal influenza vaccines (e.g., FluMist) are attenuated live vaccines and are not permitted for use.
  11. Subjects who are currently receiving long-term treatment with non-steroidal anti-inflammatory drugs (such as indomethacin, ibuprofen, etc.) or antiplatelet drugs (such as clopidogrel, ticlopidine, dipyridamole, etc.) (the use of aspirin is permitted with a maximum daily dose of 325mg).
  12. Subjects with a known history of liver diseases of significant clinical significance, including active hepatitis ( surface antigen positive and the copy number of HBV DNA > the normal value of the testing unit; virus antibody positive and the copy number of HCV RNA > the normal value of the testing unit), hepatic encephalopathy, hepatorenal syndrome, liver function at grade B or more severe cirrhosis.
  13. Subjects with a history of infection or suffering from other acquired or congenital immunodeficiency diseases.
  14. Subjects who are preparing for or have previously received tissue/organ transplantation.
  15. Subjects known to be allergic to the study drugs, monoclonal antibodies and other therapeutic protein preparations (fresh or frozen plasma, human serum albumin, cytokines, interleukins, etc.).
  16. Subjects known to have alcohol and/or drug dependence.
  17. Female subjects with a positive blood pregnancy test or those who are breastfeeding.
  18. Subjects with known signs of active bleeding in the lesions.
  19. Subjects with pleural effusion, pericardial effusion or ascites that are uncontrollable and require repeated drainage or medical intervention. Only those with a small amount of ascites shown by imaging but without symptoms can be enrolled.
  20. Subjects known to have dihydropyrimidine dehydrogenase (DPD) deficiency (or those who have experienced grade 3 or above mucosal toxicity during previous fluorouracil-containing treatments).
  21. Subjects with cardiac obstruction, pyloric obstruction or persistent and repeated vomiting (defined as vomiting ≥ 3 times within 24 hours).
  22. Subjects who had intestinal obstruction or the following diseases within 3 months prior to the first use of the study drug: inflammatory bowel disease or extensive bowel resection (partial colectomy or extensive small bowel resection accompanied by chronic diarrhea), Crohn's disease, ulcerative colitis.
  23. Subjects with a history of deep vein thrombosis, pulmonary embolism or any other serious thromboembolism within 3 months before enrollment; subjects who need to use vitamin K antagonists for anticoagulation or need to use heparin at a therapeutic dose (prophylactic dose is acceptable) during the study period.
  24. Subjects who need to use systemic therapy within 14 days prior to the first use of the study drug or during the study period, except for the following situations: intranasal, inhaled, topical steroids or local steroid injections (such as intra-articular injection); physiological doses of systemic corticosteroids (≤10mg/day prednisone or equivalent dose); short-term (≤7 days) use of steroids for the prevention or treatment of non- allergic diseases.
  25. Subjects judged by the researcher as being unsuitable for participating in this study for other reasons.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    BC001+Sintilimab+XELOX

    BC001+Sintilimab+XELOX

    Biological: BC001+Sintilimab+XELOX

Interventions

  • BiologicalBC001+Sintilimab+XELOX

    Drug pages: Sintilimab · Xelox

    patients will be given : BC001 8mg/kg, 12mg/kg or 16mg/kg intravenously once every three weeks; Sintilimab 3mg/kg(body weight\<60kg)or 200mg(body weight≥60kg)intravenously once every three weeks; Oxaliplatin 130mg/m2 intravenously once every three weeks; Capecitabine 1000mg/m2 orally once daily in the first two weeks of each three-week treatment cycle.

06

What researchers measure

Primary outcomes

  1. Adverse events

    The frequency, severity of adverse events during the trial.

    Time frame: Through study completion, assessed up to 2 years

  2. Maximum tolerated dose(dose escalation phase)

    Time frame: Until the completion of the DLT (dose-limiting toxicity) observation period, about 21 days.

  3. Recommended Phase 2 Dose(expansion phase)

    Time frame: Through study completion, assessed up to 2 years

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Time frame: 3 months

  2. VEGF concentration in serum

    Time frame: 3 months

  3. Immunogenicity

    Anti-BC001 antibody.

    Time frame: 3 months

  4. Objective response rate (ORR)

    Defined as the proportion of patients who have a complete response (CR) or a partial response (PR) per RECIST 1.1.

    Time frame: Up to 2 years

  5. Area under the curve (AUC)

    Time frame: 3 months

  6. sVEGFR in serum

    Time frame: 3 months

  7. sPD-L1 in serum

    Time frame: 3 months

  8. Progression-free survival (PFS)

    The time interval from the start of the first drug administration to progressive disease per RECIST 1.1 or death from any cause

    Time frame: Up to 2 years

  9. Overall survival (OS)

    The time interval from the first drug administration to death due to any cause.

    Time frame: Up to 5 years

  10. Duration of response (DoR)

    The time interval from the first discovery of disease remission (CR or PR) to progressive disease per RECIST 1.1 or death from any cause

    Time frame: Up to 2 years

  11. Disease control rate (DCR)

    Defined as the proportion of subjects who achieved a best response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) per RECIST 1.1.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Oct 2026, 20 months after the start.

Of 168 industry-sponsored phase 1 interventional studies under Stomach Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 65. This study's planned 20 months is below that.

Counting every sponsor, half of 243 studies reached it within 51 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 14, 2025
StartActual
Feb 28, 2025
Primary completionEst.
Oct 2026
CompletionEst.
Apr 2027
Last update
Mar 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06773312
Lead sponsor
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Feb 28, 2025
Primary completion
Oct 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Mar 10, 2025

Study contacts

Jianing Wang
Contact
wangjianing@buchangbio.com
86-13802107048
Xinlei Guo
Contact
guoxinlei@buchangbio.com
0086-10-87163362

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sintilimab · Xelox

Start the discussion